Hong Kong's Niche Sectors Signal Structural Shifts: How Institutions Are RepositioningGlobal Report·Jul 28 at 04:13 AM01099-1.53%01513-0.38%
Hong Kong Equities Flash Mixed Signals as Airlines Brace for Losses, Biotech AdvancesGlobal Report·Jul 22 at 04:18 AM02866+1.09%02402+4.37%
Biotech Breakthroughs and Data Center Hardware Pace Resilient Pockets in HK EquitiesGlobal Report·Jul 7 at 05:38 AM01513-0.38%01833+0.90%
Livzon Secures Controlling Stake in Vietnam’s Imexpharm After Tender Offer CompletionTip Ranks·May 11 at 07:46 AM01513-0.38%1595060.00%
Livzon Pharmaceutical Sets 2025 AGM to Approve Results and Cash Dividend PlanTip Ranks·Apr 23 at 09:41 AM01513-0.38%
Livzon Pharmaceutical’s First-Quarter Profit Slips as Policy Shift and Seasonality Hit RevenueTip Ranks·Apr 23 at 09:11 AM000513+0.39%01513-0.38%
CICC Reaffirms Their Buy Rating on Livzon Pharmaceutical Group (LVZPF)Tip Ranks·Apr 14 at 09:03 PM01513-0.38%159570-0.29%
LIVZON PHARMA JP-1366 tablets for the eradication of Helicobacter pylori clinical trial approvedAASTOCKS·Apr 12 at 01:01 AM512010+0.27%159316-0.18%
Livzon Pharmaceutical Schedules Board Meeting to Review First-Quarter 2026 ResultsTip Ranks·Apr 8 at 04:19 AM01513-0.38%
"Performance" LIVZON PHARMA's annual net profit is RMB 2.023 billion, down 1.8%, with a dividend of RMB 14.3 per 10 sharesAASTOCKS·Mar 24 at 10:01 AM512010+0.27%588130+0.82%
Livzon Pharmaceutical Outlines Board and Committee StructureTip Ranks·Mar 24 at 08:41 AM520690-0.28%1595060.00%
